Key indicators: measuring the Alliance's progress against its four strategic goals
Increased competition drives down prices
The GAVI business model fosters a healthy vaccine market by encouraging and pooling growing demand from developing countries, attracting new manufacturers and increasing competition to drive down prices.
In 2009, the weighted average price projection for pentavalent vaccine for 2010 fell below US$3 - a reduction of almost US$0.50 per dose compared with the year before. The price drop will allow the GAVI Alliance to vaccinate many more children against five deadly infections: diphtheria, tetanus, pertussis, Hib and hepatitis B.
Source: UNICEF Supply Division, 2010
The number of emerging market manufacturers supplying GAVI-funded vaccines has increased steadily since 2000. These manufacturers are entering the market with more affordable, yet equally effective, products.
Source: UNICEF Supply Division, 2010
See also
Related downloads
Related links
 |
 |
 |